Harpoon Therapeutics, Inc.
HARPDelisted Mar 11, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001708493
Harpoon Therapeutics, Inc. was delisted on Mar 11, 2024; its insiders filed their last Form 4 on Mar 11, 2024; 41 institutions reported holding it in 13F filings for Q4 2023, worth $175.5M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 41
- Q4 2023, +9 vs. previous quarter
- 13F value
- $175.5M
- Reported value at the end of Q4 2023
- Superinvestors holding
- 0
- At the end of Q4 2023
Superinvestors holding HARP, Q4 2023
No superinvestor reported holding HARP at the end of Q4 2023.
Latest insider trades
Open-market purchases and sales by Harpoon Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2024 (view filing)3:27 PM ET | Mar 11 | Same day | Merck Sharp & Dohme LLC and 1 other10% Owner | PPurchaseCommon Stock, par value $0.0001 | +21.4M | $23.00 | +$492.1M | New position1.00K after | |
| Oct 27, 2023 (view filing)4:41 PM ET | Oct 25 | 2 days | Lathi Vijay K and 6 others10% Owner | PPurchase | +1.37M | – | – | +1,501.3%1.46M after | |
| Oct 27, 2023 (view filing)4:41 PM ET | Oct 25 | 2 days | Lathi Vijay K and 6 others10% Owner | PPurchase | +171.5K | – | – | +76.5%395.8K after | |
| Oct 27, 2023 (view filing)4:41 PM ET | Oct 25 | 2 days | Lathi Vijay K and 6 others10% Owner | PPurchase | +686.0K | – | – | –686.0K after | Derivative |
| Oct 27, 2023 (view filing)4:41 PM ET | Oct 25 | 2 days | Lathi Vijay K and 6 others10% Owner | PPurchase | +85.8K | – | – | –85.8K after | Derivative |
| Oct 27, 2023 (view filing) | Oct 25 | 2 days | Hunt RonaldDirector, 10% Owner | PPurchase | +1.54M | – | – | New position395.8K after | 2 lots |
| Oct 27, 2023 (view filing) | Oct 25 | 2 days | Hunt RonaldDirector, 10% Owner | PPurchase | +771.8K | – | – | –85.8K after | Derivative2 lots |
| Mar 27, 2023 (view filing) | Mar 23 | 4 days | Hunt RonaldDirector, 10% Owner | PPurchase8.000% Series A Redeemable Preferred Stock | +10.0K | $1,000.00 | +$10.0M | New position10.0K after | |
| Mar 27, 2023 (view filing) | Mar 23 | 4 days | Hunt RonaldDirector, 10% Owner | PPurchase | +2.99M | – | – | –2.99M after | Derivative |
| Sep 22, 2021 (view filing) | Sep 22 | Same day | Erbez GeorgiaChief Financial Officer | PPurchase | +10.3K | $8.10 | +$83.4K | +115.5%19.2K after |
Top 10 13F holders, Q4 2023
The largest institutional positions in Harpoon Therapeutics, Inc. at the end of Q4 2023; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 2,349,060 | $22.6M | 1.08% | +2,295,000+4,245.3% | Added |
| New Leaf Venture Partners, L.L.C. | 1,859,168 | $21.1M | 17.03% | +1,543,500+489.0% | Added |
| Ra Capital Management, L.P. | 1,500,000 | $17.1M | 0.27% | +1,500,000 | New |
| Commodore Capital LP | 1,500,000 | $17.1M | 1.49% | +1,500,000 | New |
| Franklin Resources Inc | 1,492,368 | $17.0M | 0.01% | +1,360,041+1,027.8% | Added |
| Artal Group S.A. | 1,304,127 | $14.8M | 0.51% | +1,204,127+1,204.1% | Added |
| Vanguard Group Inc | 880,017 | $10.0M | 0.00% | +766,655+676.3% | Added |
| Soleus Capital Management, L.P. | 820,638 | $9.33M | 1.04% | +820,638 | New |
| Blackstone Group Inc. | 815,000 | $9.27M | 0.04% | +815,000 | New |
| Citadel Advisors LLC | 685,000 | $7.79M | 0.01% | +636,244+1,305.0% | Added |